You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Structure guided rational engineering of novel DNA reagents.

    SBC: NEW ENGLAND BIOLABS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Type II restriction enzymes (REases) are indispensible tools of modern medical research. It has long been a goal of REase manufacturers to be able to offer programmable specificity enzymes, where the sequence recognizedand resulting cutting activity can be precisely directed to any desired point in a DNA, as this will offer opportunity for improvement in many a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Medical Images, HTML5, and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. In 2010, U.S. spending on clinical trials was approximately 25 billion. Over the past decade the efficiency of clinical trials has been improved by electronic data capture (EDC) systems, whose use has increased from 38% to 61% ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Alkontrol herbal for Treating Alcohol Abuse

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. ARCHER- An Extremely Fast Medical Radiation Dose Computing Software

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTION provided by applicant The goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapy The product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computing The project is motivated by the fact that the market is ripe for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. OXAID: Oxygenating Hydrogel for Diabetic Wound Care

    SBC: O2 REGENTECH LLC            Topic: 200

    DESCRIPTION provided by applicant Oxygen plays a significant role in wound healing and maintaining elevated tissue oxygenation levels are an important factor in the dermal healing response Specifically non healing diabetic chronic wounds defined as lasting andgt weeks often show devastatingly low oxygen concentrations as low as mmHg oxygen partial pressure In the USA there are more ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Engineering stem cells to make mucopolysaccharidosis IIIB

    SBC: Phoenix Nest Inc.            Topic: 107

    DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy

    SBC: NANOPROBES INC            Topic: NIGMS

    DESCRIPTION provided by applicant We propose new probes for correlative super resolution fluorescence and electron microscopy that use biorthogonal reactions Click SNAP and HALO tags to label targets in living cells To minimize quenching of the fluorophores by the gold particles the small Undecagold gold atoms gold cluster label will be used this has minimal absorption at wavelengt ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government